RFRoseAnn Ferre

RoseAnn Ferre

*This is an algorithmically generated author record based on publicly available information.

RoseAnn Ferre has a total of 121 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modulation of the substrate preference of a MYST acetyltransferase by a scaffold protein

    by Raghuvir N. Sengupta, Oleg Brodsky, Patrick Bingham, Wade C. Diehl, RoseAnn Ferre, Samantha E. Greasley, Eric Johnson, Michelle Kraus, Whitney Lieberman, Jordan L. Meier, et al.


  • Open Access

    In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance

    by Yuao Zhu, Irina Yurgelonis, Stephen Noell, Qingyi Yang, Shunjie Guan, Zhenghui Li, Li Hao, Hussin Rothan, Devendra K. Rai, Patricia McMonagle, et al.

    To facilitate the detection and management of potential clinical antiviral resistance, in vitro selection of drug-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against the virus M pro inhibitor nirmatrelvir (Paxlovid active component) was conducted. Six M pro mutation patterns containing T304I alone or in combination with T21I, L50F, T135I, S144A, or A173V emerged, with A173V+T304I and T21I+S144A+T304I mutations showing >20-fold resistance each. Biochemical analyses indicated inhibition constant shifts aligned to antiviral results, with S144A and A173V each markedly reducing nirmatrelvir inhibition and M pro activity. SARS-CoV-2 surveillance revealed that in vitro resistance–associated mutations from our studies and those reported in the literature were rarely detected in the Global Initiative on Sharing All Influenza Data database. In the Paxlovid Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients trial, E166V was the only emergent resistance mutation, observed in three Paxlovid-treated patients, none of whom experienced COVID-19–related hospitalization or death.


  • Top Cited Papers
    Open Access

    Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants

    by Samantha E. Greasley, Stephen Noell, Olga Plotnikova, RoseAnn Ferre, Wei Liu, Ben Bolanos, Kimberly Fennell, Jennifer Nicki, Tim Craig, Yuao Zhu, et al.


  • Open Access

    Structural basis for Nirmatrelvir in vitro efficacy against SARS-CoV-2 variants

    by Samantha E Greasley, Stephen Noell, Olga Plotnikova, Rose Ann Ferre, Wei Liu, Ben Bolanos, Kimberly Fennell, Jennifer Nicki, Tim Craig, Yuao Zhu, et al.

    The COVID-19 pandemic continues to be a public health threat with emerging variants of SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2 and the active protease inhibitor in PAXLOVID ™ (nirmatrelvir tablets and ritonavir tablets). We evaluated the in vitro catalytic activity and in vitro potency of nirmatrelvir against the main protease (M pro ) of prevalent variants of concern (VOC) or variants of interest (VOI): Alpha (α, B.1.1.7), Beta (β, B.1.351), Delta (δ, B1.617.2), Gamma ( γ , P.1), Lambda (λ, B.1.1.1.37/C37), Omicron (o, B.1.1.529) as well as the original Washington or wildtype strain. These VOC/VOI carry prevalent mutations at varying frequencies in the M pro specifically for: α, β, γ (K90R), λ (G15S) and o (P132H). In vitro biochemical enzymatic assay characterization of the enzyme kinetics of the mutant M pros demonstrate that they are catalytically comparable to wildtype. Nirmatrelvir has similar potency against each mutant M pro including P132H that is observed in the Omicron variant with a Ki of 0.635 nM as compared to a Ki of 0.933nM for wildtype. The molecular basis for these observations were provided by solution-phase structural dynamics and structural determination of nirmatrelvir bound to the o, λ and β Mpro at 1.63 - 2.09 Å resolution. These in vitro data suggest that PAXLOVID has the potential to maintain plasma concentrations of nirmatrelvir many-fold times higher than the amount required to stop the SARS-CoV-2 VOC/VOI, including Omicron, from replicating in cells (1).


  • Top Cited Papers

    An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

    by Dafydd R. Owen, Charlotte M. N. Allerton, Annaliesa S. Anderson, Lisa Aschenbrenner, Melissa Avery, Simon Berritt, Britton Boras, Rhonda D. Cardin, Anthony Carlo, Karen J. Coffman, et al.

    Path to another drug against COVID-19: The rapid development of vaccines has been crucial in battling the ongoing COVID-19 pandemic. However, access challenges remain, breakthrough infections occur, and emerging variants present increased risk. Developing antiviral therapeutics is therefore a high priority for the treatment of COVID-19. Some drug candidates in clinical trials act against the viral RNA-dependent RNA polymerase, but there are other viral enzymes that have been considered good targets for inhibition by drugs. Owen et al . report the discovery and characterization of a drug against the main protease involved in the cleavage of polyproteins involved in viral replication. The drug, PF-07321332, can be administered orally, has good selectivity and safety profiles, and protects against infection in a mouse model. In a phase 1 clinical trial, the drug reached concentrations expected to inhibit the virus based on in vitro studies. It also inhibited other coronaviruses, including severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome coronavirus, and could be in the armory against future viral threats. —VV


  • Top Cited Papers

    Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor

    by Kevin Freeman-Cook, Robert L. Hoffman, Nichol Miller, Jonathan Almaden, John Chionis, Qin Zhang, Koleen Eisele, Chaoting Liu, Cathy Zhang, Nanni Huser, et al.